1. Home
  2. MNPR vs YMAB Comparison

MNPR vs YMAB Comparison

Compare MNPR & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNPR
  • YMAB
  • Stock Information
  • Founded
  • MNPR 2014
  • YMAB 2015
  • Country
  • MNPR United States
  • YMAB United States
  • Employees
  • MNPR N/A
  • YMAB N/A
  • Industry
  • MNPR Biotechnology: Pharmaceutical Preparations
  • YMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • MNPR Health Care
  • YMAB Health Care
  • Exchange
  • MNPR Nasdaq
  • YMAB Nasdaq
  • Market Cap
  • MNPR 250.0M
  • YMAB 270.5M
  • IPO Year
  • MNPR 2019
  • YMAB 2018
  • Fundamental
  • Price
  • MNPR $40.25
  • YMAB $5.72
  • Analyst Decision
  • MNPR Strong Buy
  • YMAB Strong Buy
  • Analyst Count
  • MNPR 4
  • YMAB 10
  • Target Price
  • MNPR $43.00
  • YMAB $21.10
  • AVG Volume (30 Days)
  • MNPR 71.2K
  • YMAB 542.6K
  • Earning Date
  • MNPR 03-27-2025
  • YMAB 03-04-2025
  • Dividend Yield
  • MNPR N/A
  • YMAB N/A
  • EPS Growth
  • MNPR N/A
  • YMAB N/A
  • EPS
  • MNPR N/A
  • YMAB N/A
  • Revenue
  • MNPR N/A
  • YMAB $84,553,000.00
  • Revenue This Year
  • MNPR N/A
  • YMAB $6.41
  • Revenue Next Year
  • MNPR N/A
  • YMAB $18.15
  • P/E Ratio
  • MNPR N/A
  • YMAB N/A
  • Revenue Growth
  • MNPR N/A
  • YMAB N/A
  • 52 Week Low
  • MNPR $1.72
  • YMAB $5.60
  • 52 Week High
  • MNPR $54.30
  • YMAB $20.90
  • Technical
  • Relative Strength Index (RSI)
  • MNPR 49.34
  • YMAB 35.08
  • Support Level
  • MNPR $38.80
  • YMAB $5.60
  • Resistance Level
  • MNPR $45.60
  • YMAB $6.57
  • Average True Range (ATR)
  • MNPR 5.19
  • YMAB 0.38
  • MACD
  • MNPR -1.50
  • YMAB 0.10
  • Stochastic Oscillator
  • MNPR 9.37
  • YMAB 11.43

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Share on Social Networks: